MediaPharma-Aegirbio R&D Agreement

Aegirbio AB has today signed a research & development agreement with MediaPharma Srl, an Italian biotech company focusing on novel drugs for the cure of cancer, and through this agreement Aegirbio intends to develop these drugs together with MediaPharma, in oncology and other areas. The unique characteristic of the cooperation is that Aegirbio’s Veritope technology […]

[...] Read More

Personalized medicine

At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy.

[...] Read More

Partnering

MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.

[...] Read More

MediaPharma-Aegirbio R&D Agreement Personalized medicine Partnering

Ultime News

MediaPharma-Aegirbio R&D Agreement

MP-89Zr-EV20

EV20 labeled with ⁸⁹Zr

Preclinical proof of activity established: in vivo localization of HER3+ human tumor xenografts.

Indications in Oncology
In vivo localization of HER3-expressing cancer by immuno-PET.

Pubblicato in Products

I commenti sono chiusi.

MediaPharma-Aegirbio R&D Agreement

Personalized medicine

Partnering

Highlights

Ultime News

MP-89Zr-EV20

EV20 labeled with ⁸⁹Zr

Company

R&D

Careers

Business

MediaPharma-Aegirbio R&D Agreement

Personalized medicine

Partnering

Highlights

Ultime News

MP-89Zr-EV20

EV20 labeled with 89Zr

Company

R&D

Careers

Business

EV20 labeled with ⁸⁹Zr